Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 10/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601446 | 0.80 | LRRK2 (0.37) | LRRK2IDH1MAPTGAACYP2D6 | |
| SCHEMBL3588746 | 0.76 | MAPT (0.51) | VCPMAPTGAAPLA2G1BCYP1A2 | |
| SCHEMBL3601280 | 0.76 | GRM4 (0.50) | LRRK2VCPMAPT | |
| SCHEMBL3595867 | 0.70 | MAPT (0.51) | MAPTGAALMNA | |
| SCHEMBL5729594 | 0.70 | GAA (0.46) | MAPTGAACYP1A2 | |
| SCHEMBL30265966 | 0.70 | GAA (0.46) | MAPTGAACYP1A2 | |
| SCHEMBL22273618 | 0.69 | MAP3K8 (0.53) | LRRK2CDK9MAPTGAAABCG2 | |
| SCHEMBL6483228 | 0.68 | MAPT (0.51) | LRRK2MAPTGAAPLA2G1BCYP1A2 | |
| SCHEMBL20291739 | 0.67 | MAPT (0.49) | IDH1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6987658 | 0.67 | CYP1A2 (0.44) | MAPTGAACYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | claimed |
| EP-2146970-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | Novartis Ag (CH) | 2010-01-27 | — | — | EP | claimed |
| WO-2008125627-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | claimed |
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | disclosed |
| EP-2146970-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125627-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | GPBAR1, GPER1, ADRB1 | LRRK2 2836/4885IDH1 1589/4885VCP 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.